Changes of hemostatic markers in 226 patients with disseminated intravascular coagulation (DIC) and hematopoietic disorders were examined after treatment of DIC. The changes in prothrombin time (PT) ratio, fibrinogen, fibrin and fibrinogen degradation products (FDP), antithrombin, and protein C, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), and soluble fibrin monomer complex (SFMC) in all patients with DIC were significant during the clinical course of DIC, but those of D-dimer, thrombomodulin (TM), tissue factor (TF), and tissue factor pathway inhibitor (TFPI) were not. Activated partial thromboplastin time (aPTT) and PT were significantly longer in the poor response group than in good response group. Plasma levels of FDP, TAT, PPIC, SFMC, TM, and DIC score were significantly higher in Disseminated intravascular coagulation (DIC) (1,2), which is a frequent complication in patients with leukemia, may be associated with severe bleeding and organ failure. In Japan, patients with DIC have usually been treated with heparin or with gabexate mesilate (FOY), a synthetic proteinase inhibitor (3) that inhibits the activity of thrombin, factor Xa, plasmin, and plasma kallikrein. However, the efficacy of these agents has not been sufficient (4-6). In a previ-poor response group than in good response. Protein C and antithrombin levels were significantly lower in poor response group than in good response group. The changes of PT ratio, fibrinogen, FDP, DIC score, antithrombin, plasmin inhibitor, and protein C were significant in the good response group, but these levels were not significant in the poor response group. The changes in plasma TAT and SFMC levels were significant in the good response group but were not in poor response group. The changes in D-dimer, TM, TF, or TFPI were not significant in both groups. These findings suggest that anticoagulant agents should be administered at levels below TAT 40 ng/mL or SFMC 300 Ag/mL in patients with DIC and hematopoietic disorders.
ous study, we found that therapy of DIC is more effective in pre-DIC patients than in those with established DIC. The outcome worsened with increasing DIC scores, suggesting that early diagnosis and early treatment are important (7) . Thrombin-antithrombin complex (TAT) (8) , plasmin-plasmin inhibitor complex (PPIC) (9), Ddimer (10) , soluble fibrin monomer complex (SFMC) (11) , and prothrombin fragment 1+2 (12) , which are sensitive indicators of coagulation activation or secondary fibrinosis, have recently been shown to be helpful in the diagnosis of DIC and thrombotic diseases. It was reported that vascular endothelial cell injuries markers such as thrombomodulin (TM) were significantly increased in patients with DIC and a poor outcome (13) . The changes of several hemostatic markers before the onset of DIC have been recently reported (14) . It is not well known which hemostatic markers are correlated with the outcome.
In the present study, we retrospectively examined the changes of hemostatic standard and molecular markers in 226 patients with DIC and hematopoietic disorders after treatment of DIC, to evaluate the usefulness of monitor in hemostatic changes for treatment of DIC.
MATERIALS AND METHODS
We examined the changes of hemostatic markers in 226 DIC patients with hematopoietic malignancy ( Table 1 ). The diagnosis of DIC was based on a modified version of the criteria established by the Japanese Ministry of Health and Welfare (Table 2) (15, 16) . The pre-DIC state was defined as the condition at least 1 week before the onset of DIC (16) . Patients with DIC were treated only with gabexate mesilate (FOY), a synthetic proteinase inhibitor (3, 4) that inhibits the activity of thrombin, factor Xa, plasmin, and plasma kallikrein; none of the patients were treated with heparin. Hemostatic examinations were performed before the onset of DIC as well as 1, 3, 5, 7, 10 days after onset of DIC. The efficacy of the DIC treatment was assessed after 7 days of treatment, using the DIC scores shown in Table 2 as follows. Complete remission, in which DIC score was reduced to less than that conforming with DIC criteria, and partial remission, in which DIC score decreased and symptoms were improved, but findings still conformed to DIC criteria, were considered as good response. Exacerbation in which DIC score was increased or symptoms became worse, caused death within 7 days of the beginning of treatment. Activated partial thromboplastin time (aPTT), prothrombin time (PT) ratio, fibrinogen, and fibrin and fibrinogen degradation products (FDP) were measured as described previously (17) . Antithrombin, plasmin inhibitor and protein C activities were measured by amidolytic assay, using Berichrom-Antithrombin (Behringwerke AG Marburg), Berichrom-Protein C (Behringwerke AG), Berichrom-antiplasmin (Behringwerke AG), respectively. TAT, PPIC, D-dimer, soluble fibrin monomer complex (SFMC), tissue factor (TF) (13) , tissue factor pathway inhibitor (TFPI) (18) , and thrombomodulin (TM) were determined by enzyme-linked immunosorbent assay (ELISA) using TAT-test (Teijin, Tokyo), PIC-test (Teijin), Dimer-test (Teijin), Enzymun FM test (Boehringer Mannheim GmbH, Mannheim), TF-ELISA (The Chemo-Sero-Therapeutic Research Institute, Kumamoto-city), total-TFPI-ELISA (The Chemo-Sero-Therapeutic Research Institute), and TM-test (Teijin), respectively. Data were expressed as mean + standard deviation.
Statistical difference between two groups was assessed by the Wilcoxon's rank test and that among three groups by ANOVA.
RESULTS
Out of standard markers, the changes of aPTT and protein S antigen in all patients with DIC were not significant during their clinical course, but those of PT ratio, fibrinogen, FDP, DIC score, antithrombin, and protein C in all patients with DIC were significant ( Table 3 ). Of hemostatic molecular markers, the changes of TAT, PPIC, and SFMC in those were significant, those of Ddimer, TM, TF, and TFPI were not (Table 4 ). aPTT was significantly longer in poor response group than in good response group at 1 day, 3 days, or 7 days after onset of DIC. PT was significantly longer in poor response group than in good response at all points. FDP levels were significantly higher in poor response group than in good response group 3 days or 10 days before onset of DIC. DIC score was significantly higher in poor response group than in good response group at 3 days, 5 days, 7 days, or 10 days after onset of DIC. Antithrombin levels were significantly higher in good response group than in poor response group 7 days or 10 days after onset of DIC. Protein C levels were significantly lower in poor response group than in good response group. The changes of aPTT and protein S were not significant in both good and poor response groups of DIC patients. The changes of PT ratio, fibrinogen, FDP, DIC score, antithrombin, plasmin inhibitor, and protein C were significant in good response group of DIC patients, but those were not significant in the poor response group of DIC patients (Table 5 ). Plasma TAT levels were significantly higher in the poor response group than in the good response group at 1 day, 3 days, 5 days, 7 days, or 10 days after onset of DIC. Plasma PPIC level was significantly higher in the poor response group than in good response group at 3 days after the onset of DIC. Plasma SFMC levels were significantly higher in poor response group than in good response group at 1 day, 3 days, 5 days, or 7 days before onset of DIC. Plasma TM levels were significantly higher in poor response group than in good response group at all points. There was no significant difference of plasma D-dimer, TF, or TFPI level between the two groups. The changes of plasma TAT, PPIC, and SFMC levels were significant in good response group but were not in poor response group. Changes of D-dimer, TM, TF, or TFPI were not significant in both the good and poor response group (Table 6 ). 
DISCUSSION
Monitoring the therapy of DIC is not as common as use of the International Normalized Ratio (INR) of warfarin therapy (19, 20) . In unfractionated heparin therapy, aPTT should be prolonged as long as 1.5or twofold. However, we have few monitoring tools for low-molecularweight heparin, protease inhibitor, TM, or activated protein C in the treatment of DIC. We examined the changes in hemostatic markers after treatment of DIC in patients with poor outcomes and in those with good outcomes. Of standard markers, the changes in PT ratio, fibrinogen, FDP, DIC score, antithrombin, and protein C in all patients with DIC were significant during their clinical course after treatment of DIC, suggesting that these markers are relatively useful for monitoring DIC. For hemostatic molecular markers, changes in TAT, PPIC, and SFMC were significant; those for D-dimer, TM, TF, and TFPI were not. TAT and SFMC are also considered good markers for the diagnosis of DIC (21) . The half-life of D-dimer in blood might be long. These findings suggest that TAT, PPIC, and SFMC are useful monitors for the treatment of DIC, but D-dimer, TM, TF, and TFPI were not. aPTT and PT were significantly longer in the poor response group than in the good response group. The changes in PT ratio, fibrinogen, FDP, DIC score, antithrombin, plasmin inhibitor, and protein C were significant in the good response group of DIC patients, but these markers were not significant in the poor response group, suggesting that the improvement of these markers might be a relatively useful indicator for good outcome in the treatment of DIC.
FDP and DIC score were significantly higher in the poor response group than in the good response group. Antithrombin and protein C levels were significantly lower in the poor response group than in the good response group. But since these standard deviations were too big or this range of values was narrow, these markers could not be used as a monitor for prognosis of DIC. Plasma TAT and SFMC levels were significantly higher in the poor response group than in the good response group. These findings suggest that plasma TAT levels should be less than 40 ng/mL in the treatment of DIC and that plasma SFMC levels should be below 300,g/mL. Plasma TM levels were significantly higher in the poor response group than in the good response group at all points, indicating that plasma TM levels should be below 16 ng/mL. The changes of plasma TAT and SFMC levels were significant in the good response group but were not in the poor response group. The changes of D-dimer, TM, TF, or TFPI were not significant in both groups. It might be possible that anticoagulant therapy reduces plasma levels of TAT and SFMC. Plasma TM level is considered to be the most sensitive marker for the outcome of DIC, but no drug reduces plasma TM levels significantly. There was no significant difference in plasma D-dimer, TF, or TFPI level between the two groups. Increased plasma TF and TFPI levels have been described in DIC (13, 18) , but the administration of heparin increases the plasma TFPI level (22) . Plasma TF and TFPI may be good markers for the examination of pathogenesis of DIC (23,24), but not for the outcome of DIC.
These findings suggest that high-dose anticoagulant agents should be administered in DIC patients with severe hypercoagulable states manifest as levels higher than TAT 40 ng/mL or SFMC 300 jug/mL.
